Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option.
Related news for (VAXX)
- Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
- Vaxxinity Issues Shareholder Letter
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
- Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates